Results The proportions of patients who discontinued study drug in Studies 2, 3, and 4 was 16.0% for the WEGOVY-treated group and 19.1% for the placebo-treated group, and 6.8% of patients treated with WEGOVY and 3.2% of patients treated with placebo discontinued treatment due to an adverse reaction [see Adverse Reactions (6.1)]
Safety and tolerability issues were also similar across groups, suggesting that dose adjustment is not required in patients with hepatic impairment
References and Further Reading: Tongta, S., Sungkaworn, T., & Pathomthongtaweechai, N
Not only can these areas cause discomfort and irritation, but they can also be a source of embarrassment and low confidence
Sagner recommends starting with a daily dose of 300mg, to allow the body to adjust, and then gradually increasing the dose over time based on individual goals and response. What are the best NAD supplements to buy